Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  New England Journal of Medicine

• Publication date

  2005-10-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA052306PMID 16236737
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

  2005cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• The New England Journal of Medicine における被訂正論文のインパクト

  2004cited by this paper
• The discovery of receptor tyrosine kinases: targets for cancer therapy

  2004cited by this paper
• Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

  2003cited by this paper
• Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.

  2003cited by this paper
• Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

  2002cited by this paper
• What Can We Learn from Herceptin® Trials in Metastatic Breast Cancer?

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Moving Forward: Herceptin® in the Adjuvant Setting

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

  1998cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

  1998cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

  1995cited by this paper
• Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

  1994cited by this paper
• Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor.

  1992cited by this paper
• Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

  1992cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

  1991cited by this paper
• Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases.

  1989cited by this paper
• Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

  1989cited by this paper
• p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

  1989cited by this paper
• Transesophageal echocardiography.

  1989cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

  1987cited by this paper
• Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

  1986cited by this paper
• Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

  1985cited by this paper
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

  1985cited by this paper
• Discrete sequential boundaries for clinical trials

  1983cited by this paper
• Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

  1975cited by this paper
• Humanization of an anti-p 185 HER 2 antibody for human cancer therapy ( antibody engineering / site-directed mutagenesis / c-erbB2 / neu )

  year unknowncited by this paper

• Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan.

  2026cites this paper
• CDK4/6 Inhibitors in HER2-positive Metastatic Breast Cancer.

  2026cites this paper
• Oncology data extraction with large language models from real-world breast cancer electronic health records in Spanish

  2026cites this paper
• The 19th St. Gallen international breast cancer conference ‘primary therapy of patients with early breast cancer. Evidence, controversies, consensus’: key moments and breakthroughs

  2026cites this paper
• Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access

  2026cites this paper
• Evaluating Adjuvant Radiation Therapy Survival Benefit in Early-Stage HER2-Positive Invasive Breast Cancer Following Breast-Conserving Surgery: A National Cohort Aligned with NRG-BR008 HERO Trial

  2026cites this paper
• Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

  2026cites this paper
• Signaling pathways and potential therapeutic agents in trastuzumab-induced cardiotoxicity

  2026cites this paper
• Nonadherence to changing guidelines in early breast cancer over two decades.

  2026cites this paper
• ‘Patients are left not knowing’: Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer—a qualitative study of patient experience

  2026cites this paper
• Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

  2026cites this paper
• Prediction model incorporating dynamic changes in serum tumor markers for evaluating the efficacy of neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study

  2025influential citation
• Impacts of Antibody Structure and Mixtures on Receptor Signaling for Antibody-Dependent Cellular Cytotoxicity

  2025cites this paper
• Factors associated with reduced left ventricular ejection fraction as a manifestation of Trastuzumab-induced cardiotoxicity in breast cancer patients

  2025cites this paper
• Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Sequencing, and Safety

  2025cites this paper
• Anti-HER2/Neu Antibody Therapy Inhibits HER2+ Breast Cancer by Blocking Myeloid-Derived Suppressor Cell Activity.

  2025cites this paper
• Advances in engineering immune–tumor microenvironments on-a-chip: integrative microfluidic platforms for immunotherapy and drug discovery

  2025cites this paper
• Risk of cardiovascular disease and death in patients with breast cancer receiving anthracycline-based therapy: A retrospective cohort study

  2025cites this paper
• Analysis of methylation features associated with neoadjuvant efficacy in HER2-positive breast cancer

  2025cites this paper
• The molecular blueprint of targeted radionuclide therapy

  2025cites this paper
• Safety of Permissive Cardiotoxicity of Trastuzumab in Patients with Breast Cancer: A Systematic Review and Meta-Analysis

  2025cites this paper
• The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors

  2025cites this paper
• Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study)

  2025cites this paper
• Advances in Cancer Treatment Through Nanotheranostics and Emerging Therapies

  2025cites this paper
• Genomically determined subtypes and clinicopathological features as predictors of the efficacy of preoperative chemotherapy combined with HER2-targeted therapy for early-stage HER2-positive breast cancer

  2025cites this paper
• Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab

  2025cites this paper
• Gold nanoparticle transport across tumour-associated biological barriers: in vitro models, imaging, and quantification

  2025cites this paper
• Severe trastuzumab-induced pneumonitis refractory to steroid therapy

  2025cites this paper
• Modulation of the Tumour Microenvironment by HER2 in Oesophagogastric Adenocarcinoma: Implications for Tumour Progression, Therapeutic Resistance, and Clinicopathological Outcomes

  2025cites this paper
• Phenotypic Plasticity and Competition Shape Therapy Sequencing in HER2+/HER2− Breast Cancer: A Mathematical Framework

  2025cites this paper
• Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy

  2025cites this paper
• Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization

  2025cites this paper
• HER2-low breast cancer in routine practice: a nationwide study of diagnostic variability across pathology laboratories.

  2025cites this paper
• ESMO 2024: highlights in breast cancer

  2025cites this paper
• Racial and Ethnic Disparities in Receipt of ERBB2-Targeted Therapy for Breast Cancer, 2010-2020

  2025cites this paper
• Non-coding RNAs as key regulators of epithelial-mesenchymal transition in breast cancer

  2025cites this paper
• Differences in risk factors for mortality between T2N1M0 and T3N0M0 lobular breast cancer patients: a comparative study

  2025cites this paper
• T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer—interpreting ATEMPT trial results from a clinical perspective

  2025cites this paper
• Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer

  2025cites this paper
• Evaluating the Necessity and Impact of Cardiac Imaging on Breast Cancer Care in Northwestern Ontario

  2025cites this paper
• Mapping breast cancer research on monoclonal antibodies: a data-driven approach using VOSviewer, Bibliometrix, and CiteSpace

  2025influential citation
• Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma

  2025cites this paper
• Advances in breast cancer therapy: "Exploring the therapeutic potential of CDK 4/6 inhibitors and their clinical impact."

  2025cites this paper
• Drug resistance in breast cancer: Mechanisms and strategies for management.

  2025cites this paper
• Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies

  2025cites this paper
• Healthcare costs and health outcomes analysis of Neoadjuvant Trastuzumab therapy for HER2 positive breast cancer.

  2025cites this paper
• Peptide Tags for Site‐Selective Nonenzymatic Covalent Modification of Proteins

  2025cites this paper
• Revolutionizing cancer diagnosis with computational biology in the era of digital healthcare

  2025cites this paper
• Metabolic Alterations driven by PFKFB3 upregulation confer Resistance to Trastuzumab in HER2-Positive Breast Cancer

  2025cites this paper
• Comparative study of the impact of adjuvant trastuzumab and its biosimilars on cardiac function in HER2-positive early breast cancer patients: a single-center study

  2025cites this paper
• International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-low and Ultralow Categories.

  2025cites this paper
• A serum biomarker panel for early detection of treatment-related cardiotoxicity in early HER2-positive breast cancer patients

  2025cites this paper
• Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer

  2025cites this paper
• Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.

  2025cites this paper
• CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance

  2025cites this paper
• Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy

  2025cites this paper
• 20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment.

  2025cites this paper
• Trends in local, regional and contralateral breast tumor recurrence within five years after diagnosis in the Netherlands: a population-based study including 121347 patients

  2025cites this paper
• Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab

  2025cites this paper
• Biomarkers and Cardiotoxicity in Breast Cancer

  2025cites this paper
• Optimal follow-up duration of cardiac function tests in patients treated with trastuzumab: an analysis using the Japanese Adverse Drug Event Report (JADER) database

  2025cites this paper
• Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer

  2025cites this paper
• Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance

  2025cites this paper
• Anti-PTK7 Monoclonal Antibodies Suppresses Oncogenic Phenotypes in Cellular and Xenograft Models of Triple-Negative Breast Cancer

  2025cites this paper
• Nanopore-based random genomic sampling for intraoperative molecular diagnosis

  2025cites this paper
• The Impact of Prognostic Factors on Survival in Patients with Non-Metastatic Invasive Breast Cancer: A Single-Center Experience

  2025cites this paper
• Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs

  2025cites this paper
• Seven-year overall survival of trastuzumabe versus alternative systemic therapies in a Brazilian breast cancer cohort

  2025cites this paper
• Disparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: A prognostic analysis based on real-world data comparing Brazil's public and private healthcare systems

  2025cites this paper
• Time to focus again on matrix metalloproteinases? Results of complex network analysis involving the pathophysiology of HER2-positive breast cancer

  2025cites this paper
• Dose optimisation to improve access to effective cancer medicines.

  2025cites this paper
• Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

  2025cites this paper
• Signaling pathway dysregulation in breast cancer

  2025cites this paper
• Effects of trastuzumab emtansine on canine osteosarcoma cells

  2025cites this paper
• Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer

  2025cites this paper
• Differences in treatment response and survival between HER2(2+)/FISH-positive and HER2(3+) breast cancer patients after dual-target neoadjuvant therapy: a matched case-control study

  2025cites this paper
• Cardio-Oncology and Breast Cancer Therapies

  2025cites this paper
• From chemotherapy to biotechnology: the transformation of the cancer research pipeline at Hoffmann-La Roche

  2025cites this paper
• An Overview of the Importance of Neoadjuvant Systemic Therapy for Breast Cancer Patients: From the Society of Surgical Oncology and the American Society of Breast Surgeons

  2025cites this paper
• Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer

  2025cites this paper
• Dual Inhibition of HER2 and VEGF Pathways in Breast Cancer: A Meta-analysis of Outcomes.

  2025cites this paper
• Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study

  2025cites this paper
• YAP as a therapeutic target to reverse trastuzumab resistance

  2025cites this paper
• Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data

  2025cites this paper
• Comparison of pathological complete response (pCR) between short-term (<6 cycles) and long-term (≥6 cycles) neoadjuvant trastuzumab therapy for HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Long Durable Response With Trastuzumab Deruxtecan Monotherapy in a Triple-Negative Metastatic Breast Cancer Patient With Human Epidermal Growth Factor Receptor 2 Mutation: A Long-Term Follow-Up and Literature Review

  2025cites this paper
• Establishment and Partial Characterization of Canine Mammary Tumor Cell Lines

  2025cites this paper
• Breast Cancer Surgery at a Tertiary Center in Greece: Clinicopathological Associations and Patient Outcomes

  2025cites this paper
• Trends in the Management of Small HER2-Positive Breast Cancers

  2025cites this paper
• Optimization of pharmaceutical research and development by early-phase assessment of investigational medicinal products.

  2025cites this paper
• Cardiac function surveillance practices and outcomes in patients with HER2-positive breast cancer treated with trastuzumab: a retrospective cohort study across a safety-net and tertiary care setting

  2025cites this paper
• Capturing breast cancers’ copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond

  2025cites this paper
• Organometallic conjugates of artesunate: synthesis and evaluation of anticancer potential

  2025cites this paper
• Efficacy and Predictability of Cyclin-Dependent Kinase 4/6 Inhibitors in HER2-Positive Breast Cancer

  2025cites this paper
• Clinical efficacy of pyrotinib combined with chemotherapy for neoadjuvant treatment in HER2-positive breast cancer: a single-center study

  2025cites this paper
• Alzheimer's disease outlook: controversies and future directions.

  2025cites this paper
• An Evaluation of HER2 Expression Heterogeneity in Primary Tumors and Metastatic Lymph Nodes of Patients With Advanced Extramammary Paget's Disease: Prognostic and Therapeutic Implications

  2025cites this paper
• A Comprehensive Analysis of Adverse Events Associated with HER2 Inhibitors Approved for Breast Cancer Using the FDA Adverse Event Report System (FAERS)

  2025cites this paper
• Monoclonal Antibodies: Production, Therapeutic Applications and Real World Case Study in Cancer Management

  2025cites this paper
• CD44v, S1PR1, HER3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb

  2025cites this paper